- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
Patent holdings for IPC class C07K 14/71
Total number of patents in this class: 2325
10-year publication summary
|
146
|
164
|
175
|
158
|
237
|
254
|
203
|
176
|
192
|
120
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Acceleron Pharma Inc. | 339 |
136 |
| Regeneron Pharmaceuticals, Inc. | 4902 |
129 |
| Amgen Inc. | 4499 |
36 |
| The Regents of the University of California | 21018 |
35 |
| Keros Therapeutics, Inc. | 82 |
32 |
| Immatics Biotechnologies GmbH | 1128 |
31 |
| The Trustees of the University of Pennsylvania | 4453 |
25 |
| Immunitybio, Inc. | 519 |
23 |
| Board of Regents, The University of Texas System | 6231 |
22 |
| The Board of Trustees of the Leland Stanford Junior University | 6754 |
21 |
| City of Hope | 1051 |
21 |
| Precigen Inc | 109 |
20 |
| Genentech, Inc. | 4167 |
19 |
| The Johns Hopkins University | 5972 |
19 |
| Genzyme Corporation | 1381 |
19 |
| Biocon Limited | 220 |
17 |
| Seattle Children's Hospital | 97 |
17 |
| Levicept Ltd | 32 |
16 |
| Novartis AG | 10162 |
14 |
| National Research Council of Canada | 1557 |
14 |
| Other owners | 1659 |